Crossmark

The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe

Crossref DOI link: https://doi.org/10.1186/s12876-020-1164-0

Published Online: 2020-01-21

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Armuzzi, Alessandro

Tarallo, Miriam

Lucas, James

Bluff, Daniel

Hoskin, Benjamin

Bargo, Danielle

Cappelleri, Joseph C.

Salese, Leonardo

daCosta DiBonaventura, Marco https://orcid.org/0000-0002-8333-4676
Funding

Funding for this research was provided by:

Pfizer Inc
License Information

Text and Data Mining valid from 2020-01-21

Version of Record valid from 2020-01-21
More Information

Article History

Received: 27 June 2019

Accepted: 6 January 2020

First Online: 21 January 2020

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: AA has been involved in advisory boards for, and received research support from, Pfizer Inc; and has received research support from MSD and Takeda; lecture fees from AbbVie, Amgen, AstraZeneca, Chiesi, Ferring, Hospira, Janssen, Medtronic, MSD, Mundipharma, Nikkiso, Otsuka, Pfizer Inc, Takeda, TiGenix, and Zambon; and consultancy fees from AbbVie, Allergan, Amgen, Biogen Idec, Bristol-Myers Squibb, Celgene, Celltrion, Eli Lilly, Ferring, Hospira, Janssen, MSD, Mundipharma, Mylan, Pfizer Inc, Samsung Bioepis, Sandoz, Sofar, and Takeda. JL, DBl, and BH acted as consultants for Pfizer Inc. MD, MT, DBa, JCC, and LS are employees and stockholders of Pfizer Inc.

Document is current

Any future updates will be listed below